No transcript available for this episode.
This episode examines the FDA’s policy shift allowing clinical decision support software to bypass premarket review, the convergence of three regulatory deadlines in February 2026 that impose manufacturer-grade compliance on radiology groups customizing AI workflows, and new clearances for RapidAI’s neurovascular imaging modules, BrainSpace’s adaptive hydrocephalus management system, and UltraSight’s multi-platform cardiac ultrasound program. The briefing details how HTI-1 transparency requirements, ISO 13485 quality management standards, and Recovery Audit Contractor enforcement are reshaping operational accountability for health systems deploying AI-enabled clinical interventions.